LEADER 02182nam  2200577Ia 450 
001 9910782959603321
005 20230617034924.0
010   $a1-280-06161-8
010   $a9786610061617
010   $a1-4175-2628-9
010   $a92-4-068105-1
035   $a(CKB)1000000000005522
035   $a(SSID)ssj0000209852
035   $a(PQKBManifestationID)11189720
035   $a(PQKBTitleCode)TC0000209852
035   $a(PQKBWorkID)10266771
035   $a(PQKB)10126811
035   $a(MiAaPQ)EBC284617
035   $a(Au-PeEL)EBL284617
035   $a(CaPaEBR)ebr10062376
035   $a(CaONFJC)MIL6161
035   $a(OCoLC)476034745
035   $a(EXLCZ)991000000000005522
100   $a20040924d2004      my             0
101 0 $aeng
135   $aurcn|||||||||
181   $ctxt
182   $cc
183   $acr
200 00$aNeuroscience of psychoactive substance use and dependence$b[electronic resource] /$fWorld Health Organization
210   $aGeneva $cWorld Health Organization$dc2004
215   $axx, 264 p. $cill
300   $aBibliographic Level Mode of Issuance: Monograph
311   $a92-4-156235-8 
320   $aIncludes bibliographical references and index.
327   $aIntroduction -- Brain mechanisms: neurobiology and neuroanatomy -- Biobehavioural processes underlying dependence -- Psychopharmacology of dependence for different drug classes -- Genetic basis of substance dependence -- Concurrent disorders -- Ethical issues in neuroscience research on substance dependence treatment and prevention -- Conclusion and implications for public health policy.
606   $aPsychotropic drugs$xPhysiological effect
606   $aSubstance abuse$xPhysiological effect
606   $aPsychopharmacology
615  0$aPsychotropic drugs$xPhysiological effect.
615  0$aSubstance abuse$xPhysiological effect.
615  0$aPsychopharmacology.
676   $a615/.788
712 02$aWorld Health Organization.
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910782959603321
996   $aNeuroscience of psychoactive substance use and dependence$93723274
997   $aUNINA